Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
HFA 23: IRONMAN: Anemia, Iron Deficiency and Quality of Life
Author(s): Paul Kalra Added: 11 months ago
ESC-HFA 23 – Prof Paul Kalra (Portsmouth Hospitals NHS Trust, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562). The IRONMAN trial aimed to study the effectiveness of intravenous iron in patients with heart failure and iron deficiency when compared to standard care. It showed that administration of IV FDI led to lower rates of recurrent heart failure hospitalisations and… View more

Heart Failure
HFA 23: TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure
Author(s): Stephen J Greene Added: 11 months ago
ESC-HFA 23 — Dr Stephen Greene (Duke University School of Medicine, US) outlines the findings from the QoL study of the TRANSFORM-HF Trial (NCT03296813). The TRANSFORM-HF trial is a randomized trial which compared torsemide to furosemide as a treatment for patients with heart failure. Around 2859 patients with heart failure were enrolled in the trial, whose clinical outcomes were measured across… View more

Heart Failure
Determinants of Functional Capacity and Quality of Life After Implantation of a Durable Left Ventricular Assist Device
Author(s): Kiran K Mirza , Finn Gustafsson Added: 3 years ago
According to the third report from the International Society for Heart and Lung Transplantation (ISHLT) Mechanically Assisted Circulatory Support Registry, more than 15,500 left ventricular assist devices (LVADs) were implanted worldwide between 2013 and 2017.1 Originally, LVADs were exclusively implanted as part of a bridge to transplantation (BTT) strategy, but in recent years a large… View more

Heart Failure
Author(s): Martin R Cowie , Michel Komajda Added: 3 years ago
Advances in diagnosis and treatment have improved the outlook for the estimated 26 million patients with heart failure (HF) worldwide,1 but there remains a continuing need for further reduction in mortality and hospitalisation and the associated social and financial consequences of the disease. In a European study of outcomes after HF hospitalisation, 17 % of patients died within 12 months and 44… View more

Heart Failure

Prevention & Chronic Conditions
Paul A Heidenreich
Dr. Paul Heidenreich, a distinguished professional in the field of cardiology, serves as a Professor and Vice Chair for Quality within the Department of Medicine. Additionally, he holds the esteemed position of Chief of Medicine at the VA Palo Alto Health Care System. With a background in non-invasive cardiology, he actively practices as a cardiologist while engaging in clinical research. Dr… View more
John McNeill
Job title: Professor and head of School of Public Health and Preventive Medicine
After graduating in medicine from the University of Adelaide Professor McNeil undertook specialist training to become qualified as a consultant in internal medicine and clinical pharmacology. He completed a PhD in Clinical Pharmacology at Melbourne University and was awarded a National Heart Foundation overseas postgraduate research scholarship to study epidemiology at the London School of… View more
ACC 22: Results From the EMPULSE Study
Author(s): Mikhail Kosiborod Added: 2 years ago
In this short interview, Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) summarises the main findings of the EMPULSE study, originally presented as a late-breaking trial at ACC.22(NCT04157751). The study investigated the effects of empagliflozin on symptoms,physical limitations and quality of life inacute heart failure. The trial demonstrated that treatment with empagliflozin… View more

Heart Failure
HFA 23: DAPA-HF and DELIVER: KCCQ in Pts with Varying Ejection Fraction
Author(s): Ankeet Bhatt Added: 11 months ago
ESC-HFA 2023 - Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, US) joins us onsite to discuss a study that looked into Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in patients with varying ejection fractions, that were enrolled in the DELIVER and DAPA-HF trials. This study used pooled, patient-level data from the DAPA-HF and DELIVER studies, aiming to examine the… View more

Heart Failure
ACC 2022 Late-breaker Discussion: The SODIUM-HF Trial
Author(s): Justin Ezekowitz , Harriette Van Spall Added: 2 years ago
In this in-depth conversational interview, Late-breaker host Dr Harriette Van Spall(McMaster University, CA) meets PI, Dr Justin A. Ezekowitz (University of Alberta, CA) to discuss the SODIUM-HF trial (CT02012179). The aim of the trial was to evaluate the effects of a low-sodium diet, compared to usual care in patients with heart failure. Presented first at ACC.22, the trial showed that reducing… View more

Heart Failure

Prevention & Chronic Conditions
HF 22: 6M Results of a No-Implant Interatrial Shunt in Pts With Chronic HF
Author(s): Lars H Lund Added: 1 year ago
Prof Lars Lund (Karolinska Institute, SE) outlines the findings of the ALLEVIATE-HF-1 and ALLEVIATE-HF-2 studies at 6 months. Presented at Heart Failure 22, this study aimed to evaluate a no-implant shunt in patients with chronic heart failure. Discussion Points: 1. Aims of This Study 2. No-Implant Interatrial Shunt 3. Inclusion and Exclusion Criteria, Patient Cohort and Study Design 4. Key… View more

Heart Failure